Compare BTU & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | TMDX |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2001 | 2019 |
| Metric | BTU | TMDX |
|---|---|---|
| Price | $23.77 | $83.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $32.83 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 2.4M | 937.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | ★ $3,861,500,000.00 | $605,494,000.00 |
| Revenue This Year | $17.96 | $24.25 |
| Revenue Next Year | $5.47 | $18.75 |
| P/E Ratio | ★ N/A | $131.49 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $15.67 | $60.11 |
| 52 Week High | $41.14 | $156.00 |
| Indicator | BTU | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 58.69 |
| Support Level | $21.98 | $66.18 |
| Resistance Level | $24.53 | $140.79 |
| Average True Range (ATR) | 1.00 | 4.14 |
| MACD | 0.15 | 0.63 |
| Stochastic Oscillator | 77.40 | 79.36 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.